Updated just now · Live
Stock analysis, price data, and AI-powered insights for Nektar Therapeutics (NKTR).
Nektar Therapeutics operates in the Pharmaceuticals sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for NKTR.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). NKTR Stock Intelligence Report. [stoxpulse.com/stocks/nktr]
Disclaimer: The information on this page about Nektar Therapeutics (NKTR) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Nektar Therapeutics.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Citigroup Maintains Buy on Nektar Therapeutics, Ra...
6h ago
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstei...
8h ago
StoxPulse AI results for NKTR: Pulse Score 46/100. Primary sentiment trends from 14 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$2.88B
P/E Ratio
—
EPS
$-1.87
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Citigroup Maintains Buy on Nektar Therapeutics, Raises Price Target to $151
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
Wedbush Maintains Neutral on Nektar Therapeutics, Raises Price Target to $95
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development
Nektar Therapeutics announces proposed public offering
Nektar Therapeutics Launches $250M Common Stock Offering
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata - Slideshow
These stocks are gapping in today's session